Hoth Therapeutics Stock Analysis

Hoth Stock Analysis Notes

The company has price-to-book (P/B) ratio of 1.77. Some equities with similar Price to Book (P/B) outperform the market in the long run. Hoth Therapeutics recorded a loss per share of 1.02. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 26th of October 2022. Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York. Hoth Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. To learn more about Hoth Therapeutics call the company at 646 756 2997 or check out https://hoththerapeutics.com.

Hoth Therapeutics Investment Alerts

Hoth Largest EPS Surprises

View All Earnings Estimates

Hoth Stock Institutional Investors

Note, although Hoth Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Hoth Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 14.46 M.

Hoth Profitablity

Management Efficiency

Hoth Therapeutics has return on total asset (ROA) of (0.8446) % which means that it has lost $0.8446 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5113) %, meaning that it created substantial loss on money invested by shareholders. Hoth Therapeutics' management efficiency ratios could be used to measure how well Hoth Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1. The current Return On Capital Employed is estimated to decrease to -1.13. As of now, Hoth Therapeutics' Net Tangible Assets are increasing as compared to previous years. The Hoth Therapeutics' current Debt To Assets is estimated to increase to 0.01, while Total Assets are projected to decrease to under 6.3 M.

Technical Drivers

As of the 13th of February 2026, Hoth Therapeutics retains the Risk Adjusted Performance of (0.05), market risk adjusted performance of (0.17), and Standard Deviation of 3.78. Hoth Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Hoth Therapeutics Price Movement Analysis

Hoth Therapeutics Insider Trading Activities

Hoth Therapeutics Outstanding Bonds

Hoth Therapeutics Predictive Daily Indicators

Hoth Therapeutics Forecast Models

Hoth Therapeutics' time-series forecasting models are one of many Hoth Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Hoth Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Hoth Therapeutics Bond Ratings

Hoth Therapeutics financial ratings play a critical role in determining how much Hoth Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Hoth Therapeutics' borrowing costs.

Hoth Therapeutics Debt to Cash Allocation

Hoth Therapeutics currently holds 31.07 K in liabilities with Debt to Equity (D/E) ratio of 2.01, implying the company greatly relies on financing operations through barrowing. Hoth Therapeutics has a current ratio of 15.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Hoth Therapeutics' use of debt, we should always consider it together with its cash and equity.

Hoth Therapeutics Total Assets Over Time

Hoth Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Hoth Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Hoth Therapeutics Debt Ratio

0.52

It feels like most of the Hoth Therapeutics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Hoth Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Hoth Therapeutics, which in turn will lower the firm's financial flexibility.

Hoth Therapeutics Corporate Bonds Issued

Hoth Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Hoth Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Hoth shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Hoth Therapeutics. By using and applying Hoth Stock analysis, traders can create a robust methodology for identifying Hoth entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Hoth analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Hoth analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Hoth Therapeutics stock analysis indicators help investors evaluate how Hoth Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Hoth Therapeutics shares will generate the highest return on investment. By understating and applying Hoth Therapeutics stock analysis, traders can identify Hoth Therapeutics position entry and exit signals to maximize returns.

When running Hoth Therapeutics' price analysis, check to measure Hoth Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hoth Therapeutics is operating at the current time. Most of Hoth Therapeutics' value examination focuses on studying past and present price action to predict the probability of Hoth Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hoth Therapeutics' price. Additionally, you may evaluate how the addition of Hoth Therapeutics to your portfolios can decrease your overall portfolio volatility.